Processa Pharma

Coming – December 9

Two Validated Targets. A Growing Immunology Pipeline

Date and Time

December 9

–

12:00 PM ET / 9:00 AM PT

Details will be shared with confirmed attendees

About this Event

Building a Differentiated Pipeline in Immunology and Inflammation

Join us for an Executive Briefing with Sheila Gujrathi, MD, Executive Chair of Processa Pharmaceuticals (NASDAQ: PCSA), exploring the company’s expanding pipeline of investigational therapies targeting immunological and inflammatory diseases.

Following its acquisition of Vidya Therapeutics and approximately $200 million in institutional financing, Processa is advancing two distinct therapeutic programs built around clinically validated mechanisms.

Its lead candidate, VT-7208, is an investigational, low-dose, once-daily oral BTK inhibitor being developed across three indications: food allergies, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (MS).

Processa is also expanding its pipeline through a collaboration with Generian Pharmaceuticals to advance a preclinical oral FcRn antagonist. FcRn is a validated target in autoimmune disease, and an effective oral treatment could offer an alternative to existing injectable therapies.

During this briefing, Dr. Gujrathi will discuss:
  • Two validated therapeutic targets: How BTK and FcRn support Processa’s broader immunology strategy.
  • Three potential indications for VT-7208: Food allergies, CSU, and relapsing MS.
  • Upcoming clinical milestones: Anticipated Phase 2 results beginning in late 2027, with additional milestones targeted for 2028 and 2029.
  • Financial position: How approximately $200 million in institutional financing supports the company’s development plans.

Discover how Processa is building a differentiated immunology pipeline with multiple potential clinical development opportunities.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.